Chevy Chase Trust Holdings LLC Lowers Stake in Johnson & Johnson (NYSE:JNJ)

Chevy Chase Trust Holdings LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,399,101 shares of the company’s stock after selling 77,760 shares during the period. Johnson & Johnson accounts for 0.6% of Chevy Chase Trust Holdings LLC’s portfolio, making the stock its 25th largest position. Chevy Chase Trust Holdings LLC’s holdings in Johnson & Johnson were worth $202,338,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. IFS Advisors LLC grew its holdings in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson in the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson in the 3rd quarter worth $35,000. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson in the 4th quarter worth $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC grew its holdings in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after acquiring an additional 91 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $156.20 on Tuesday. The stock has a market cap of $376.08 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The firm’s 50-day simple moving average is $147.87 and its two-hundred day simple moving average is $155.95.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the prior year, the company earned $2.29 earnings per share. The business’s revenue was up 5.3% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Stifel Nicolaus cut their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, January 23rd. Guggenheim raised their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Finally, Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.